EUVIMEDEUVIMED entdecken
LeserbriefVergleichsstudie

Comparative Effectiveness of Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients with De Novo Heart Failure with Mildly Reduced and Preserved Ejection Fraction

Ankeet S Bhatt, Muthiah Vaduganathan, Barada Prasad Jena, Sylwia Suminska, Carlos Eid, Rahul Khairnar, Gabriella Farries, Michele Senni

European Journal of Heart Failure · 2024

DOI: 10.1002/ejhf.3233 ↗

Kurz gefasst

Leserbrief in der Zeitschrift European Journal of Heart Failure, 2024. Verfasst von Ankeet S Bhatt und 7 weiteren Autor:innen. Beteiligte Einrichtung: Kaiser Permanente San Francisco Medical Center and Division of Research, San Francisco, CA, USA. Hauptthemen laut MEDLINE: Valsartan, Heart Failure, Aminobutyrates, Biphenyl Compounds. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben. Gefördert von: Novartis AG, Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ValsartanHeart FailureAminobutyratesBiphenyl CompoundsStroke VolumeDrug CombinationsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsTetrazolesHumansTreatment OutcomeMaleFemaleAged

Substanzen

ValsartanAminobutyratesBiphenyl Compoundssacubitril and valsartan sodium hydrate drug combinationDrug CombinationsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsTetrazoles

Autor:innen und Institutionen

  • Kaiser Permanente San Francisco Medical Center and Division of Research, San Francisco, CA, USA.
  • Division of Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto, CA, USA.
  • Brigham and Women's Hospital, Heart and Vascular Center, Boston, MA, USA.
  • Novartis Global Service Center, Hyderabad, India.
  • Novartis Corporate Center, Dublin, Ireland.
  • Novartis Pharma Services AG, Office Middle East and North Africa, Nairobi, Kenya.

Förderung

  • Novartis AG
  • Novartis

Zitieren

APA

Bhatt, A. S., Vaduganathan, M., Jena, B. P., Suminska, S., Eid, C., Khairnar, R., Farries, G., & Senni, M. (2024). Comparative Effectiveness of Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients with De Novo Heart Failure with Mildly Reduced and Preserved Ejection Fraction. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3233

Vancouver

Bhatt AS, Vaduganathan M, Jena BP, Suminska S, Eid C, Khairnar R, et al. Comparative Effectiveness of Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients with De Novo Heart Failure with Mildly Reduced and Preserved Ejection Fraction. European Journal of Heart Failure. 2024. doi:10.1002/ejhf.3233

BibTeX
@article{Bhatt2024,
  author = {Bhatt, Ankeet S and Vaduganathan, Muthiah and Jena, Barada Prasad and Suminska, Sylwia and Eid, Carlos and Khairnar, Rahul and Farries, Gabriella and Senni, Michele},
  title = {Comparative Effectiveness of Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients with De Novo Heart Failure with Mildly Reduced and Preserved Ejection Fraction},
  journal = {European Journal of Heart Failure},
  year = {2024},
  doi = {10.1002/ejhf.3233}
}
Kostenlos starten →